Why a Theranostics No-Show Hurts Differently Than an IMRT One

Why AI Is Not a One-Time Purchase in Radiation Oncology

AI purchasing differs fundamentally from traditional capital and software decisions. The cost is not the license, it is the recurring monitoring as the model drifts in ways no tolerance table catches. From hype to value: how to evaluate AI for long-term cost structure, clinical accountability, and organizational readiness, not the demo. medsolvedynamics.com [http://medsolvedynamics.com] | team@medsolvedynamics.com [team@medsolvedynamics.com]  #RadiationOncology #AIinHealthcare #OncologyLeadership #HealthcareAI

Why a Theranostics No-Show Hurts Differently Than an IMRT One

In radiation oncology, a curative no-show is a slot you backfill. In theranostics, the Lu-177 dose is a fixed amount with about a five-day shelf life, scheduled for one patient, and it cannot wait for a better day. Here is how scheduling discipline, authorized user coverage, and capture mechanics determine whether a theranostics service line holds its margin, and the two operating costs the vendor proforma leaves out. medsolvedynamics.com [http://medsolvedynamics.com] | team@medsolvedynamics.com [team@medsolvedynamics.com]  #Theranostics #RadiationOncology #RadiopharmaceuticalTherapy #OncologyOperations

A Guideline Says It Is Appropriate. The Next Question Is Whether Your Program Can Deliver It.

A society guideline on low-dose radiation for osteoarthritis makes benign disease a real service-line conversation in radiation oncology. Clinical appropriateness and program readiness are different questions. Here is the operational and financial read: the referral pathway, the payer coverage and prior-authorization pathway, and using open LINAC capacity for incremental benign volume without affecting the curative schedule. medsolvedynamics.com [http://medsolvedynamics.com] | team@medsolvedynamics.com [team@medsolvedynamics.com]  #RadiationOncology #Osteoarthritis #ServiceLineGrowth #BenignDisease

The Service Contract Renewal Conversation Most Rad Onc Programs Have Already Lost

Most rad onc programs walk into a service contract renewal with no independent numbers on the table. The vendor brings their performance data. The program nods. The renewal runs the vendor's direction. The gap is not in the contract language. It is in the measurement asymmetry. Five metrics the vendor tracks and the program rarely does. Uptime delivered against contracted spec. Response time against contracted SLA. Preventive maintenance hours delivered against contracted hours. Parts coverage against parts billed extra. First-call resolution rate. Pull the data quarterly, reconcile against contract spec, build the quarterly service review around the gap. medsolvedynamics.com [http://medsolvedynamics.com]  |  team@medsolvedynamics.com [team@medsolvedynamics.com]

The Vendor Landscape Just Widened. Your Capital Conversation Changed Whether You Know It Or Not.

At ESTRO 2026, United Imaging showed a CE-marked uRT-linac 506c on the show floor. Diagnostic-CT integrated with a linear accelerator on a single platform. Online adaptive radiotherapy positioned without an MR-linac, without a third-party planning system, and without RaySearch. Reported as CE marked in Europe. Not yet in the US market. Capital decisions in flight in the US in 2026 are not changing because of what showed up in Berlin. What changed is the leverage map on every conversation around them. medsolvedynamics.com [http://medsolvedynamics.com]  |  team@medsolvedynamics.com [team@medsolvedynamics.com]